Top Markets
Coin of the day
CSL Limited CSL Limited

CSL Limited

CSL
株式のランク #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
株価
$99.32
時価総額
$48.20B
変化(1日)
0.98%
変化(1年)
-32.14%
AU
取引 CSL Limited (CSL)

カテゴリー

CSL Limited(CSL)の利益
Dec 2025 時点の利益 TTM: $1.61B
CSL Limited の最新の財務報告によると、同社の現在の利益は $1.61B です。2024 年には $3.38B の利益を上げ、これは 2023 年の利益 $2.66B と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
CSL Limited の利益の推移(2000 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $1.61B -56.65%
2025 $3.72B 10.34%
2024 $3.38B 26.74%
2023 $2.66B -4.19%
2022 $2.78B -6.80%
2021 $2.98B 15.92%
2020 $2.57B 9.89%
2019 $2.34B 2.63%
2018 $2.28B 35.00%
2017 $1.69B 8.61%
2016 $1.56B -9.22%
2015 $1.71B 6.84%
2014 $1.60B 19.64%
2013 $1.34B 5.36%
2012 $1.27B -7.31%
2011 $1.37B 38.29%
2010 $992.87M 11.00%
2009 $894.45M 2.37%
2008 $873.74M 56.73%
2007 $557.47M 493.43%
2006 $93.94M -74.77%
2005 $372.39M 201.20%
2004 $123.64M 168.99%
2003 $45.96M -7.38%
2002 $49.63M -8.38%
2001 $54.17M 88.04%
2000 $28.81M 0.00%
同業他社の利益
企業 利益 利益の差
$20.51B 1,170.24%
DK
$4.64B 187.63%
US
$5.23B 224.03%
US
$2.14B 32.42%
BE
$1.45B -10.11%
NL